Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Cell/Gene Tx channel feed
Eyeing a trio of trial initiations, Jim Wilson's gene therapy startup woos Bruce Goldsmith from Deerfield as CEO
6 years ago
People
Deerfield vaults to the top of cell and gene therapy CDMO game with $1.1B facility at Philadelphia's newest biopharma hub
6 years ago
Outsourcing
At #JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell
6 years ago
R&D
In Focus
With $110M to add to the bankroll, Generation Bio sets its sights on engineering a revolution in the gene therapy field
6 years ago
Financing
Chinese court sentences Jiankui He to 3 years in jail — and confirms birth of 3rd CRISPR baby
6 years ago
China
Flagship bankrolls quest to create gene therapy 2.0, with new viral delivery tech in hand
6 years ago
Financing
Startups
Inside Astellas' $3B Audentes gene therapy acquisition: coded messages, a bidding war and $77M for the CEO
6 years ago
Deals
UK antitrust watchdog clears Roche/Spark deal — but what is the FTC thinking?
6 years ago
Deals
Jury finds Gilead liable for $585M and big royalties in Kite CAR-T patent case
6 years ago
Kite Pharma's ex-CEO contradicts founder as CAR-T patent trial heats up, with conflicting valuations
6 years ago
Bristol-Myers is making a bee-line to the FDA with positive liso-cel data — but is it too late in the CAR-T game?
6 years ago
R&D
Patient #9 has been a concern, but Sangamo and Pfizer are bullish about winning the marathon hemophilia A gene therapy race
6 years ago
R&D
J&J team shows off 'breakthrough' BCMA CAR-T data, and that could cause a big headache at bluebird and Bristol-Myers
6 years ago
R&D
With FDA review of its gene therapy underway, Ferring's $570M spinout delivers in PhIII bladder cancer readout
6 years ago
R&D
Novartis, Vertex outline big gene therapy plans — fueling a global boom
6 years ago
In a landmark first glimpse of human data from Vertex, CRISPR/Cas9 gene therapy signals early benefit
6 years ago
R&D
Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront
6 years ago
Deals
FDA puts Solid Bio’s lead gene therapy program on hold — again — after another patient is hurt by SGT-001
6 years ago
R&D
Decrying 'arbitrary and capricious' action, RegenxBio sues FDA over clinical holds on gene therapy
6 years ago
FDA+
RegenxBio runs into partial hold for anti-VEGF gene therapy as FDA investigates delivery device
6 years ago
FDA+
Thermo Fisher hooks gut onto its gene therapy pipeline, inks new collaboration pact
6 years ago
Novartis takes a hit as FDA orders a hold on Zolgensma trials in wake of fresh safety concerns
6 years ago
Pharma
FDA+
Sean Parker helps create a CRISPRed cell therapy 2.0 play — and he’s got a high-profile set of leaders on the team
6 years ago
Financing
Startups
Exclusive: GSK’s Hal Barron allies with Rick Klausner’s $600M cell therapy startup, looking to break new ground blitzing solid tumors
6 years ago
Deals
First page
Previous page
49
50
51
52
53
54
55
Next page
Last page